Proteasome inhibitor Bortezomib/Velcade has emerged as an effective anticancer therapy for the treatment of relapsed and/or refractory multiple myeloma (MM), but prolonged treatment can be associated ...
0052 – Fubon Taiwan Technology Tracker – Check 0052 price, review total assets, see historical growth, and review the analyst rating from Morningstar.
Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) This is an ASCO Meeting ...
Explore detailed information about 0052's dividend performance, find the 0052 dividend history and ex-dividend date. This page offers a comprehensive view of 0052's dividend yield payout trends and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results